We may earn commissions if you use the recommended services on this site.  

Noramco Acquires Cambrex Drug Product Business Unit

Latest Business News

Noramco Completes Acquisition of Cambrex Drug Product Business Unit

Noramco, a global active pharmaceutical ingredients (API) manufacturer specializing in controlled substances, has announced the successful acquisition of the Cambrex Drug Product Business Unit, previously known as Halo Pharmaceuticals. This acquisition expands Noramco's service offerings for API customers, providing them with additional options for drug product formulation development, clinical and commercial manufacturing, and packaging. The facilities in Mirabel, Québec, and Whippany, New Jersey will support these expanded capabilities. As part of the acquisition, Noramco will return to operating under the Halo Pharmaceutical brand.

Enhanced Service Options

The acquisition enables Noramco and its subsidiary Purisys to offer customers a broader range of sourcing options beyond APIs. With these additional capabilities, Noramco/Purisys customers can now develop drug product formulations for their APIs for both clinical and commercial purposes. Noramco CEO Lee Karras expressed enthusiasm for the acquisition, highlighting the company's direct appreciation of the capabilities of both sites and the potential to work with existing and future customers.

About Noramco and Purisys

Noramco, headquartered in Wilmington, Delaware, is a global supplier of APIs, including controlled substances, to the pharmaceutical industry. Its APIs are used by leading brand and generic pharma companies, as well as small to mid-scale pharma companies, in over 350 products across more than 30 countries. Purisys, based in Athens, Georgia, is a leading supplier of API CDMO services and pharmaceutical reference standards. The company's manufacturing facility and innovation center specialize in complex high-barrier custom synthetic chemistry and support the development of custom APIs for various clinical and niche commercial applications. In conclusion, Noramco's acquisition of the Cambrex Drug Product Business Unit expands its capabilities and service offerings, allowing it to better serve its API customers. The integration of Halo Pharmaceuticals and the expertise of Purisys position Noramco to meet the evolving needs of the pharmaceutical industry and provide comprehensive solutions for drug product development and manufacturing.

Hot Take: The Impact of Noramco's Acquisition on New Pharmaceutical Businesses

Noramco's acquisition of the Cambrex Drug Product Business Unit, formerly known as Halo Pharmaceuticals, is a significant move that will undoubtedly shape the landscape for new businesses in the pharmaceutical industry.

Expanded Service Offerings

The acquisition broadens Noramco's service offerings, providing API customers with more options for drug product formulation development, clinical and commercial manufacturing, and packaging. This expansion could set a new industry standard, pushing new businesses to diversify their services to compete effectively.
Increased Competition
Furthermore, Noramco's return to the Halo Pharmaceutical brand and the integration of Purisys' expertise could strengthen the company's position in the market, making it a formidable competitor for new entrants. New businesses will need to demonstrate unique value propositions to differentiate themselves and attract customers in this increasingly competitive space.
Opportunities for Collaboration
However, the acquisition also presents opportunities. The enthusiasm expressed by Noramco's CEO for working with existing and future customers suggests potential for partnerships and collaborations. New businesses could leverage this openness to form strategic alliances, fostering innovation and growth in the industry. In conclusion, while Noramco's acquisition presents challenges for new businesses, it also opens up opportunities for those able to adapt and innovate in this evolving pharmaceutical landscape.
Story First Published at: https://financialpost.com/pmn/business-wire-news-releases-pmn/noramco-announces-the-acquisition-of-the-cambrex-drug-product-business-unit
Brought to you by BusinessFormation.io
Know Your State's Registered Agent Requirements: What is a Registered Agent
Learn How To Create An LLC: What Is An LLC and How To Start an LLC Online
Business Formation Services: View Top 3 Online LLC Filing Companies

LLC Filing & Registered Agent Services

Compare Online LLC Filing Services Today

We work with the market leaders in business formation and registered agent services.

Getting started is simple and inexpensive. Form your business today & secure your brand name before someone beats you to it! Click below to view the Top 3 Best LLC and registered agent service providers.
View Top 3 Providers Now

Filing An LLC Can Be Complicated

Streamline Your LLC Filing Online for $39

Northwest Registered Agent is the best-rated service for first time filers.

Get professional LLC formation & registered agent services for only $39 + state filing fee. This offers includes your full LLC setup, plus a private business address, lifetime support, and more.

Trusted by Millions. Save 82% Today.